Abstract
Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer. Drugs that target epidermal growth factor receptor (EGFR = ErbB1) and/or ErbB2 have demonstrated effect against breast, colorectal, lung, pancreatic and head and neck carcinomas, and are currently in clinical use. Part of the anti-tumor effect of the ErbB inhibitor drugs has been suggested to derive from inhibition of tumor angiogenesis. There are several proposed mechanisms by which the ErbB inhibiting agents may regulate tumor neovascularization although most of them are currently not fully characterized. This review addresses the role of ErbB signaling in angiogenesis, as well as the anti-angiogenic mechanisms of ErbB targeted cancer drugs.
Keywords: Anti-angiogenic drugs, cancer, EGFR, endothelial cells, HER, monoclonal antibodies, pericytes, smooth muscle cells, tyrosine kinase inhibitors
Current Vascular Pharmacology
Title: ErbB Targeted Drugs and Angiogenesis
Volume: 8 Issue: 3
Author(s): Erika Iivanainen and Klaus Elenius
Affiliation:
Keywords: Anti-angiogenic drugs, cancer, EGFR, endothelial cells, HER, monoclonal antibodies, pericytes, smooth muscle cells, tyrosine kinase inhibitors
Abstract: Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer. Drugs that target epidermal growth factor receptor (EGFR = ErbB1) and/or ErbB2 have demonstrated effect against breast, colorectal, lung, pancreatic and head and neck carcinomas, and are currently in clinical use. Part of the anti-tumor effect of the ErbB inhibitor drugs has been suggested to derive from inhibition of tumor angiogenesis. There are several proposed mechanisms by which the ErbB inhibiting agents may regulate tumor neovascularization although most of them are currently not fully characterized. This review addresses the role of ErbB signaling in angiogenesis, as well as the anti-angiogenic mechanisms of ErbB targeted cancer drugs.
Export Options
About this article
Cite this article as:
Iivanainen Erika and Elenius Klaus, ErbB Targeted Drugs and Angiogenesis, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112241
DOI https://dx.doi.org/10.2174/157016110791112241 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer
Current Drug Targets Vitamin D and Cancer Stem Cells in the Gastrointestinal Tract
Current Medicinal Chemistry Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology